Corient Private Wealth LP Makes New $7.16 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Corient Private Wealth initiated a $7.16 million position in Alnylam Pharmaceuticals during the second quarter by purchasing 23,797 shares. Institutional investors collectively own approximately 92.97% of ALNY’s outstanding stock.
• Alnylam reported quarterly earnings of $1.84 per share, beating estimates of $1.63, while revenue increased 66.9% year over year to $1.29 billion, slightly below expectations.
• Analyst sentiment remains positive but price targets have been reduced: the stock has a “Moderate Buy” consensus rating and an average target of $386.14, compared with an opening price of $237.10.

Corient Private Wealth LP purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 23,797 shares of the biopharmaceutical company's stock, valued at approximately $7,163,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ALNY. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Finally, Manchester Capital Management LLC grew its position in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $237.10 on Monday. The firm has a market cap of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. The firm's fifty day moving average is $262.62 and its 200 day moving average is $293.54. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the firm posted ($0.51) earnings per share. The firm's revenue for the quarter was up 66.9% on a year-over-year basis. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ALNY shares. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Stifel Nicolaus cut their price objective on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating for the company in a report on Friday, July 31st. Raymond James Financial upgraded Alnylam Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a $420.00 price objective on the stock in a research report on Monday, August 3rd. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. Finally, Oppenheimer decreased their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source